MedPath

Interdisciplinary Weight Loss Therapy Associate With the Use of Interactive Digital Technology

Not Applicable
Conditions
Obesity
Interventions
Other: Interdisciplinary intervention in obesity
Registration Number
NCT04034472
Lead Sponsor
Federal University of São Paulo
Brief Summary

Obesity is a complex disease associate to metabolic alterations, which may lead to cardiometabolic risk in women with obesity. The use of interactive digital technology as adjuvante tool to the clinical practices in weight loss therapy emerges as an innovative strategy. However, it was note fully investigated if this kind of approach can contribute to improve inflammatory state and metabolic alterations in obese population.

Detailed Description

This study consists in a 12-week clinical interdisciplinary weight loss therapy, with endocrinologist, nutritionist, psychologist and exercise physiologist to evaluate the effects of clinical interdisciplinary therapy associated to use the eletronic means on inflammatory biomarkers and metabolic alterations in women with obesity.

The present study was composed by a sample of obese women (20 to 45 years old), recruited through advertisements in the media (newspapers, magazines, radio, television and social media - Twitter®, Facebook® and Instagram®). The volunteers lived in the city of São Paulo or nearby, so they could attend monthly the University on the days of the clinical, nutritional, psychological and exercise evaluations, counseling, educational sessions and motivational strategies supporting adherence. To complete the Education Behaviors Program the volunteers follow weekly the instructions found in the Platform #12Semanas®. All participants met the inclusion criteria for the obesity profile according to the World Health Organization (WHO), presenting Body Mass Index (BMI) values above 30 kg/m². Patients with any pathology that could compromise the results of the study (heart disease, musculoskeletal deformities, diseases related to the immune system, genetic, metabolic or endocrine diseases, identified by the physician) were not included in the study. Anthropometric measures, body composition by bio-impedance and bood samples were collected to serum analysis.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
80
Inclusion Criteria
  • obesity diagnosis;
  • body mass index (BMI) values above 30 kg/m²
  • adult
  • aged 20-45 years
Exclusion Criteria
  • presence of heart diseases
  • musculoskeletal deformities
  • diseases related to the immune system

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Cardiometabolic risk in women with obesityInterdisciplinary intervention in obesityThe use of interactive digital technology as adjuvant tool to the clinical practices in weight loss therapy emerges as an innovative strategy. However. it was note fully investigated if this can contribute to decrease inflammatory markers in obese women. In the present investigate it was amied to evaluate the effects of clinical approach associated to use of electronic means on inflammatory markers in women with obesity.
Primary Outcome Measures
NameTimeMethod
Body Lean mass (kg)12 weeks

Body lean mass was measured by Bio-impedance meter (BIA) by the device BIODYNAMICS 310e (TBW®).

Basal Metabolic Rate (KJ/day)12 weeks

Basal Metabolic Rate was estimated by Bio-impedance meter (BIA) - device BIODYNAMICS 310e (TBW®).

Insulin Concentration12 weeks

Blood samples were collected at the outpatient clinic at approximately 8:00 A.M. after an overnight fast (12h). Insulin concentration were available by commercial kits. Insulin resistance was assessed using the homeostasis model assessment-insulin resistance (HOMA-IR). The cutoff value determined for Brazilian population is HOMA-IR\>2.71 for classifying the subjects with insulin resistance.

Human Fibroblast Growth Factor 2112 weeks

Blood samples were collected at the outpatient clinic at approximately 8:00 A.M. after an overnight fast (12h). The assays of Human Fibroblast Growth Factor 21 (FGF-21) concentration were determined by ELISA.

Adiponectin12 weeks

Blood samples were collected at the outpatient clinic at approximately 8:00 A.M. after an overnight fast (12h). The assays of adiponectin concentration were determined by ELISA.

Atrial Natriuretic Peptide12 weeks

Blood samples were collected at the outpatient clinic at approximately 8:00 A.M. after an overnight fast (12h). The assays of atrial natriuretic peptide (ANP) concentration were determined by ELISA.

Leptin12 weeks

Blood samples were collected at the outpatient clinic at approximately 8:00 A.M. after an overnight fast (12h). The assays of leptin concentration were determined by ELISA.

Body weight (kg)12 weeks

Body weight was measured using light clothes and barefoot on a Filizola® scale to 0,1kg and capacity of 180kg.

Body Fat mass (kg)12 weeks

Body fat mass was measured by Bio-impedance meter (BIA) by the device BIODYNAMICS 310e (TBW®).

Glucose Concentration12 weeks

Blood samples were collected at the outpatient clinic at approximately 8:00 A.M. after an overnight fast (12h). Glucose concentration were available by commercial kits.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Universidade Federal de São Paulo

🇧🇷

São Paulo, SP, Brazil

© Copyright 2025. All Rights Reserved by MedPath